Breckenridge Patent-Cliff Exposure & CMS Drug Spending Portfolio

Breckenridge (US): 25 reconciled FDA prescription therapies, $138.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies25
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$138.6M
2024 Medicare Part D Spend$109.5M
2024 Medicaid Spend$29.1M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel